Genetic targeting or pharmacologic inhibition of NADPH oxidase nox4 provides renoprotection in long-term diabetic nephropathy.
about
The Nucleotide Oligomerization Domain-Like Receptors in Kidney InjuryRedox Signaling in Diabetic Nephropathy: Hypertrophy versus Death Choices in Mesangial Cells and PodocytesPharmacology and Clinical Drug Candidates in Redox MedicineThe balance of powers: Redox regulation of fibrogenic pathways in kidney injuryEvolution of NADPH Oxidase Inhibitors: Selectivity and Mechanisms for Target EngagementReactive Oxygen-Related Diseases: Therapeutic Targets and Emerging Clinical IndicationsRole of NADPH Oxidase in Metabolic Disease-Related Renal Injury: An UpdateTargeting Mitochondria and Reactive Oxygen Species-Driven Pathogenesis in Diabetic NephropathyObesity and Diabetic Kidney Disease: Role of Oxidant Stress and Redox BalanceMitochondrial hormesis and diabetic complicationsUpdates of reactive oxygen species in melanoma etiology and progression.Inhibition of NOX1/4 with GKT137831: a potential novel treatment to attenuate neuroglial cell inflammation in the retina.Combined NOX1/4 inhibition with GKT137831 in mice provides dose-dependent reno- and atheroprotection even in established micro- and macrovascular disease.Nox-4 deletion reduces oxidative stress and injury by PKC-α-associated mechanisms in diabetic nephropathy.Reactive oxygen species as important determinants of medullary flow, sodium excretion, and hypertensionUpstream regulators and downstream effectors of NADPH oxidases as novel therapeutic targets for diabetic kidney disease.p47(phox) contributes to albuminuria and kidney fibrosis in mice.Targeting NADPH oxidase with a novel dual Nox1/Nox4 inhibitor attenuates renal pathology in type 1 diabetes.Nox Inhibitors & Therapies: Rational Design of Peptidic and Small Molecule InhibitorsMyocardin-related Transcription Factor Regulates Nox4 Protein Expression: LINKING CYTOSKELETAL ORGANIZATION TO REDOX STATE.Effects of p67phox on the mitochondrial oxidative state in the kidney of Dahl salt-sensitive rats: optical fluorescence 3-D cryoimagingMechanisms of bradykinin-induced expression of connective tissue growth factor and nephrin in podocytes.Evidence of the Importance of Nox4 in Production of Hypertension in Dahl Salt-Sensitive Rats.Metabolomics Reveals a Key Role for Fumarate in Mediating the Effects of NADPH Oxidase 4 in Diabetic Kidney DiseaseActivation of endothelial NAD(P)H oxidase accelerates early glomerular injury in diabetic miceCorosolic acid inhibits the proliferation of glomerular mesangial cells and protects against diabetic renal damageNADPH Oxidase-4 Overexpression Is Associated With Epithelial Ciliary Dysfunction in Neutrophilic AsthmaPathophysiology of gadolinium-associated systemic fibrosisDiabetes and Kidney Disease: Role of Oxidative Stress.mTORC2 Signaling Regulates Nox4-Induced Podocyte Depletion in Diabetes.NADPH oxidase 4 deficiency increases tubular cell death during acute ischemic reperfusion injury.Inhibition of the processing of miR-25 by HIPK2-Phosphorylated-MeCP2 induces NOX4 in early diabetic nephropathy.Advances and strategies in NADPH oxidase inhibitors and activators patents.Novel effective drugs for diabetic kidney disease? or not?Nox and renal disease.APX-115, a first-in-class pan-NADPH oxidase (Nox) inhibitor, protects db/db mice from renal injury.Are reactive oxygen species still the basis for diabetic complications?Dissecting fibrosis: therapeutic insights from the small-molecule toolbox.Glucose Homeostasis and Cardiovascular Alterations in Diabetes.Canonical Transient Receptor Potential 6 Channel: A New Target of Reactive Oxygen Species in Renal Physiology and Pathology.
P2860
Q26740429-85E81D4F-52E4-4EA9-BDCD-F3B14A43554BQ26778527-F480A250-57C8-4DDC-803D-467FF743CB53Q26785525-6DB8C2A0-52BA-4687-830C-075A2F9D3106Q26786137-28AE62BF-EEC7-46F0-B600-23145EF4F070Q26861119-2F1AC437-AB72-4AAF-A0FD-2A0C6D294477Q27024762-CB21A873-9361-4E9A-A922-E4B54373F784Q28074668-273FDDAC-C242-440E-9FF5-68371FFFD526Q28083205-CADC53DC-9CC6-4B17-880B-39F46AF5B643Q28385322-AC866B8A-3052-44DE-B8C6-2435C43E2FCFQ28388387-A03CE3C9-1BE7-48E7-ADD0-7D9C2C2D4619Q34403921-D73A985A-81DF-420C-9959-A97A250BD6B1Q34487307-417DD41C-0A7D-46B7-A26F-9A4C16AAA2DBQ34550600-A5A1F487-DD4F-4B68-92FE-6F5338540131Q34631886-D53F872D-2D2A-456D-BB53-6DC9D4E58C7FQ35035263-202C5374-BD0F-43BE-8ED0-750485C264C6Q35450699-42851835-35C2-4D21-B328-068B67C60BA2Q35587361-C7C13E52-5227-45D2-A7C8-4A581F73409FQ35671828-27827746-385D-41CC-AC22-904FDA5F64CDQ35824748-5192B557-1E0F-4672-8425-DF1074DF1D1AQ35837331-36B0D86F-4CB1-4156-B53E-FC78C82A6CB8Q36132556-F0701BD4-64DA-4B54-A878-F81362437F1BQ36345943-456EEC0D-F3CE-4CFF-9253-C8E9F32E72C8Q36463802-B4863D96-82A7-4527-A59A-FBBE547EFED2Q36514979-C48ACB1B-2590-4C38-8253-F344462E8C50Q36921163-0BD66E54-BADC-4BF2-9AAE-9411C402DB2EQ36941304-71B1B74A-70F8-46E6-A9C0-E4B75CC80D23Q36970970-66C99ECF-58EE-44B5-80BA-3BC5139FCBEBQ37139482-D9AB4D55-66AC-46D3-AD7F-45743174F8C2Q37349206-621FDCC1-A8AF-43C0-9EDA-810C5CA3AFAEQ37365132-B21D8CD7-5FCE-4D86-AB55-E524A8CB43B5Q37479906-52964E96-3304-4414-BFB4-95FC23C8676FQ37493523-B02F483B-0645-4CD2-8D22-C7D7222C8EF5Q38257747-C4EF1C86-71C6-4B1A-AD47-53750E7144A4Q38265818-0E8AE766-8A98-43C1-BD5C-3E0C5AF64B15Q38335626-464BF1EA-968D-4945-8C25-F5324219A50CQ38406031-539E86C1-1056-4237-8757-57CBCFCDDAFDQ38451253-7A55700D-0821-424A-B72B-6DCB5C416A04Q38580461-1A35E68A-DD90-4869-9F1A-B7CA9E865651Q38596700-BC291C1E-BCD6-4AAB-82C3-27BF83573F46Q38758929-A56575EA-6178-491F-A33B-99765D22268A
P2860
Genetic targeting or pharmacologic inhibition of NADPH oxidase nox4 provides renoprotection in long-term diabetic nephropathy.
description
2014 nî lūn-bûn
@nan
2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Genetic targeting or pharmacol ...... ong-term diabetic nephropathy.
@ast
Genetic targeting or pharmacol ...... ong-term diabetic nephropathy.
@en
type
label
Genetic targeting or pharmacol ...... ong-term diabetic nephropathy.
@ast
Genetic targeting or pharmacol ...... ong-term diabetic nephropathy.
@en
prefLabel
Genetic targeting or pharmacol ...... ong-term diabetic nephropathy.
@ast
Genetic targeting or pharmacol ...... ong-term diabetic nephropathy.
@en
P2093
P2860
P356
P1476
Genetic targeting or pharmacol ...... ong-term diabetic nephropathy.
@en
P2093
Cedric Szyndralewiez
David Barit
Freddy Heitz
Harald H H W Schmidt
Karin A Jandeleit-Dahm
Kirstin Wingler
Mark E Cooper
Stephen P Gray
P2860
P304
P356
10.1681/ASN.2013070810
P577
2014-02-07T00:00:00Z